CEO Kelly Wilson and President Robert Wilson resign; Noreen Griffin appointed CEO

Biostax Corp.

Robert Wilson resigned as President on July 25, 2023; no dispute cited.
Kelly Wilson resigned as CEO on July 25, 2023; appointed President same day.
Noreen Griffin named CEO under consulting agreement; monthly fee $20,834, deferred until $1M funding threshold with 8.5% interest.
Griffin, age 70, previously VP of company and former CEO; family ties to both Wilson executives.
Kelly Wilson's compensation continues under prior consulting agreement dated November 1, 2022.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert Wilson

President

Biostax Corp.

Effective: 2023-07-25
Filed: September 13, 2023, 7:59 PM ET

On July 25, 2023, Robert Wilson, President and director of Immune Therapeutics, Inc. d/b/a Biostax Corp. (the “Company”), delivered a letter of resignation to the Company, pursuant to which Mr. Wilson resigned as President of the Company, effective immediately.

Departed

Kelly Wilson

Chief Executive Officer

Biostax Corp.

Effective: 2023-07-25
Successor: Noreen Griffin
Filed: September 13, 2023, 7:59 PM ET

On July 25, 2023, Kelly Wilson, Chief Executive Officer and Chief Operating Officer of Company, delivered a letter of resignation to the Company, pursuant to which Ms. Wilson resigned as Chief Executive Officer of the Company, effective immediately.

Appointed

Noreen Griffin

Chief Executive Officer

Biostax Corp.

Effective: 2023-07-25
Filed: September 13, 2023, 7:59 PM ET

On July 25, 2023, the Board of the Company appointed Noreen Griffin as Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Wilson resigned as President at Biostax Corp..

Action: resigned
Role: President

Exact text from the filing

On July 25, 2023, Robert Wilson, President and director of Immune Therapeutics, Inc. d/b/a Biostax Corp. (the “Company”), delivered a letter of resignation to the Company, pursuant to which Mr. Wilson resigned as President of the Company, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kelly Wilson resigned as Chief Executive Officer at Biostax Corp..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

On July 25, 2023, Kelly Wilson, Chief Executive Officer and Chief Operating Officer of Company, delivered a letter of resignation to the Company, pursuant to which Ms. Wilson resigned as Chief Executive Officer of the Company, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Noreen Griffin was appointed as Chief Executive Officer at Biostax Corp..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On July 25, 2023, the Board of the Company appointed Noreen Griffin as Chief Executive Officer.

View on SEC.gov

Source: SEC EDGAR

accession 0001493152-23-032514

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.